Immunomedics announces new patents for ADC, vaccines for cancer therapy
Immunomedics announced the issuance of U.S. Patent 9,458,242 for additional claims under the patent family "Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity." This new patent, which will expire in July 2033, covers the use of labetuzumab govitecan, the company's second investigational antibody-drug conjugate, or ADC, for solid cancer therapy. Labetuzumab govitecan is composed of SN-38, the active metabolite of irinotecan, an FDA approved chemotherapy for colorectal cancer, linked to labetuzumab, the company's humanized antibody that targets the carcinoembryonic antigen, which is expressed on colorectal and other solid cancers. This ADC, at the 10 mg/kg dose level, has been active in the therapy of patients with metastatic colorectal cancer who had failed multiple prior therapies, including irinotecan.